Global Cell Surface Markers Market

Cell Surface Markers Market Size, Share, Growth Analysis, By Product (Antibody, PCR Array), By Source (Human, Mouse), By Application (Research, Clinical), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35J2099 | Region: Global | Published Date: December, 2024
Pages: 157 | Tables: 60 | Figures: 75

Cell Surface Markers Market News

  • In January 2023, GenScript announced the expansion of its portfolio with the launch of the UltraMAB Discovery Antibody Platform, offering high-quality monoclonal antibodies for research and diagnostic applications.
  • In July 2022, Bio-Rad Laboratories introduced the ZE5 Cell Analyzer, a flow cytometer combining high-performance detection with an intuitive user interface.
  • In April 2022, BD launched the BD Rhapsody Whole Transcriptome Analysis (WTA) Amplification Kit, providing high-quality data for single-cell transcriptome analysis.
  • In November 2021, Thermo Fisher Scientific announced the launch of the Attune™ Dx Flow Cytometer, a clinical-grade platform for in vitro diagnostic use.
  • In October 2021, F. Hoffman-La Roche received FDA approval for the VENTANA PD-L1 (SP263) Assay as a companion diagnostic for identifying patients with triple-negative breast cancer eligible for immunotherapy.
  • In September 2021, QIAGEN N.V. expanded its portfolio with the launch of the QIAseq FastSelect –rRNA HMR Kits, enabling efficient depletion of ribosomal RNA from RNA-seq libraries.
  • In August 2021, Grifols SA announced the acquisition of Tiancheng (China) to expand its presence in the Chinese market and strengthen its position in blood transfusion diagnostics.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Cell Surface Markers Market size was valued at USD 27.9 billion in 2022 and is poised to grow from USD 30.13 billion in 2023 to USD 55.77 billion by 2031, growing at a CAGR of 8.0% during the forecast period (2024-2031).

The competitive landscape of the global cell surface markers market is characterized by intense competition among players striving to enhance their product portfolios, expand their geographical presence, and strengthen their market positions. Market players focus on technological advancements, collaborations, partnerships, and acquisitions to gain a competitive edge. Additionally, investments in research and development activities to develop innovative cell analysis techniques and improve the specificity and sensitivity of cell surface marker detection are prominent. The market is highly fragmented, with a mix of established players and emerging companies. As the market continues to grow, competition is expected to intensify, driving players to differentiate themselves through product innovation and strategic alliances. 'Abbott Laboratories ', 'Beckman Coulter Inc. (Danaher Corporation) ', 'Becton, Dickinson and Company (BD) ', 'Bio-Rad Laboratories Inc. ', 'F. Hoffmann-La Roche Ltd ', 'Grifols SA ', 'Immucor Inc. ', 'Nihon Kohden Corporation ', 'Thermo Fisher Scientific Inc. ', 'Siemens Healthineers ', 'Sysmex Corporation ', 'Qiagen NV ', 'Agilent Technologies Inc. ', 'Luminex Corporation (DiaSorin SpA) ', 'Miltenyi Biotec ', 'Novus Biologicals ', 'Cell Signaling Technology (CST) ', 'Stemcell Technologies ', 'Fluidigm Corporation (Standard BioTools)'

One key driver of the global cell surface markers market is the increasing prevalence of chronic diseases. The rising incidence of chronic diseases, such as cancer, cardiovascular diseases, and autoimmune disorders, drives the demand for cell surface markers. These markers play a crucial role in disease diagnosis, prognosis, and targeted therapies, aiding in personalized medicine approaches. The growing burden of chronic diseases worldwide fuels the demand for advanced cell analysis techniques and drives the overall market growth.

Increasing focus on personalized medicine: One key market trend in the global cell surface markers market is the increasing focus on personalized medicine. Personalized medicine aims to tailor medical treatments to individual patients based on their unique characteristics, including cell surface markers. Cell surface markers play a vital role in identifying specific cell populations and determining their response to therapies. The growing understanding of the role of cell surface markers in disease progression and treatment response has led to the development of targeted therapies that can be customized based on an individual's cell surface marker profile. This trend towards personalized medicine is driving the demand for advanced cell analysis techniques and innovative cell surface marker detection methods in the market.

North America dominated the global cell surface markers market. North America has a well-established healthcare infrastructure, a strong presence of leading pharmaceutical and biotechnology companies, and a high level of research and development activities. The region also witnesses significant investments in advanced technologies, such as flow cytometry and other cell analysis techniques, driving the demand for cell surface markers. Moreover, favorable government initiatives, supportive reimbursement policies, and a robust regulatory framework contribute to the dominance of North America in the market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Cell Surface Markers Market

Report ID: SQMIG35J2099

$5,300
BUY NOW GET FREE SAMPLE